Sales growth for Indian generic versions of weight-loss drug semaglutide slowed to 4.4% in June, down from 15.3% in May. Data suggests doctors and patients are increasingly preferring the established brand, Ozempic, as the generic market becomes crowded and price differences shrink.
The competitive landscape for weight-loss and diabetes treatments in India is shifting as innovator brands, particularly those marketed by Novo Nordisk, reclaim market share. Recent data indicates that the initial rapid growth experienced by Indian generic versions of semaglutide is losing momentum. In June, unit sales growth for these generic alternatives dropped to 4.4%, a sharp decline from the 15.3% growth recorded in May. In contrast, established innovator brands have maintained a more predictable and steady performance.
Factors Influencing Prescriber Choice
A primary driver for this shift is the narrowing price gap between original semaglutide injectables and many leading Indian generic options. When the cost difference is minimal, medical professionals often favor the innovator brand due to its established reputation for quality and long-standing clinical history. Novo Nordisk previously implemented strategic price adjustments following the expiry of certain patent protections, which surprised many domestic manufacturers at the time. This move appears to have effectively countered the aggressive entry of lower-cost generic alternatives.
Market Saturation in the Generic Segment
The Indian generic market for semaglutide has become increasingly crowded, leading to internal competition that dilutes the effectiveness of individual generic brands. As multiple companies enter the space, they often compete for the same patient pool, which can limit the growth potential for any single generic manufacturer. Additionally, strong brand recognition plays a significant role in patient and physician behavior. Many patients associate the drug primarily with the brand name Ozempic, making them more comfortable paying a slight premium for the original product rather than switching to a lesser-known generic.
For investors, this trend highlights the challenges generic pharmaceutical companies face when entering high-profile, innovator-led segments. While the potential demand for weight-loss and diabetes treatments remains high, the ability to gain long-term market share depends on factors beyond just lower pricing, including brand trust and consistent supply. The next important monitorable will be whether generic manufacturers can differentiate their products through marketing or further price cuts to regain momentum, or if the market will continue to consolidate around established innovators.